Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma

Overview of attention for article published in Frontiers in endocrinology, October 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 19 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 21,407 followers.

Uso de TKIs como terapia neoadyuvante en #cancerDeTiroides localmente avanzado e irresecable: ⬇️ más del 70% en tamaño que permite resección posterior. Muy interesante en tumores con pocas opciones terapéuticas 👏👏👏@jgarcialeman @SeenTiro

23 Oct 2019

Reply Repost Favourite

RT @FrontEndocrinol: New Research: Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma: Back…

23 Oct 2019

Reply Repost Favourite

RT @FrontEndocrinol: New Research: Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma: Back…

23 Oct 2019

Reply Repost Favourite

New Research: Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma: Background: Papillary thyroid carcinoma (PTC) is the most common and less aggressive thyroid cancer, but some patients… https://t.co/TmHu2vSsG

23 Oct 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.